Physician profile
Daniel Pedersen
NPI 1285899880
$488.99
in general payments reported to CMS, 2019-2025
10 companies · $47.77 in 2025
The $47.77 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $28.06 · 2023: $194 · 2024: $28.11 · 2025: $47.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.21 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154.28 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $115.28 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $79.66 | 2021-2023 | Jardiance, Mounjaro |
| Novo Nordisk INC | $36.67 | 2021-2025 | |
| Exact Sciences Corporation | $29.91 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $17.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2021 | |
| Halozyme INC | $14.24 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.25 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pedersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.